Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
BIOL's Cash to Debt is ranked higher than
98% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.03 vs. BIOL: No Debt )
BIOL' s 10-Year Cash to Debt Range
Min: 0.08   Max: No Debt
Current: No Debt

Equity to Asset 0.37
BIOL's Equity to Asset is ranked higher than
82% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. BIOL: 0.37 )
BIOL' s 10-Year Equity to Asset Range
Min: -0.35   Max: 0.91
Current: 0.37

-0.35
0.91
F-Score: 3
Z-Score: -2.66
M-Score: -3.29
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -37.65
BIOL's Operating margin (%) is ranked higher than
53% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.92 vs. BIOL: -37.65 )
BIOL' s 10-Year Operating margin (%) Range
Min: -357.14   Max: 14.2
Current: -37.65

-357.14
14.2
Net-margin (%) -39.71
BIOL's Net-margin (%) is ranked higher than
54% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.36 vs. BIOL: -39.71 )
BIOL' s 10-Year Net-margin (%) Range
Min: -686.67   Max: 39.05
Current: -39.71

-686.67
39.05
ROE (%) -128.66
BIOL's ROE (%) is ranked lower than
51% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.53 vs. BIOL: -128.66 )
BIOL' s 10-Year ROE (%) Range
Min: -6372.65   Max: 110.88
Current: -128.66

-6372.65
110.88
ROA (%) -53.95
BIOL's ROA (%) is ranked higher than
50% of the 294 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.87 vs. BIOL: -53.95 )
BIOL' s 10-Year ROA (%) Range
Min: -282.19   Max: 62.83
Current: -53.95

-282.19
62.83
ROC (Joel Greenblatt) (%) -276.99
BIOL's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. BIOL: -276.99 )
BIOL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -495.62   Max: 222.6
Current: -276.99

-495.62
222.6
Revenue Growth (3Y)(%) 21.30
BIOL's Revenue Growth (3Y)(%) is ranked higher than
57% of the 259 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. BIOL: 21.30 )
BIOL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -27.9   Max: 105.4
Current: 21.3

-27.9
105.4
EBITDA Growth (3Y)(%) -6.40
BIOL's EBITDA Growth (3Y)(%) is ranked higher than
97% of the 225 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. BIOL: -6.40 )
BIOL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -49.5   Max: 100
Current: -6.4

-49.5
100
EPS Growth (3Y)(%) -8.00
BIOL's EPS Growth (3Y)(%) is ranked higher than
95% of the 221 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. BIOL: -8.00 )
BIOL' s 10-Year EPS Growth (3Y)(%) Range
Min: -54.3   Max: 148.4
Current: -8

-54.3
148.4
» BIOL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

BIOL Guru Trades in Q1 2014

John Burbank 20,661 sh (New)
Mario Gabelli 91,455 sh (unchged)
» More
Q2 2014

BIOL Guru Trades in Q2 2014

George Soros 30,949 sh (New)
Mario Gabelli 91,455 sh (unchged)
John Burbank Sold Out
» More
Q3 2014

BIOL Guru Trades in Q3 2014

Mario Gabelli 91,455 sh (unchged)
George Soros Sold Out
» More
Q4 2014

BIOL Guru Trades in Q4 2014

Mario Gabelli 91,455 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with BIOL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 10.09
BIOL's Forward P/E is ranked higher than
97% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 33.56 vs. BIOL: 10.09 )
N/A
P/B 2.10
BIOL's P/B is ranked higher than
81% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.70 vs. BIOL: 2.10 )
BIOL' s 10-Year P/B Range
Min: 0.87   Max: 42.47
Current: 2.1

0.87
42.47
P/S 1.80
BIOL's P/S is ranked higher than
81% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.99 vs. BIOL: 1.80 )
BIOL' s 10-Year P/S Range
Min: 0.13   Max: 6.01
Current: 1.8

0.13
6.01
EV-to-EBIT -5.25
BIOL's EV-to-EBIT is ranked lower than
58% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.15 vs. BIOL: -5.25 )
BIOL' s 10-Year EV-to-EBIT Range
Min: -62.9   Max: 73
Current: -5.25

-62.9
73
Current Ratio 1.41
BIOL's Current Ratio is ranked higher than
82% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.62 vs. BIOL: 1.41 )
BIOL' s 10-Year Current Ratio Range
Min: 0.63   Max: 8.29
Current: 1.41

0.63
8.29
Quick Ratio 0.75
BIOL's Quick Ratio is ranked higher than
81% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.79 vs. BIOL: 0.75 )
BIOL' s 10-Year Quick Ratio Range
Min: 0.34   Max: 7.75
Current: 0.75

0.34
7.75
Days Inventory 147.13
BIOL's Days Inventory is ranked higher than
65% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 123.27 vs. BIOL: 147.13 )
BIOL' s 10-Year Days Inventory Range
Min: 68.7   Max: 407.12
Current: 147.13

68.7
407.12
Days Sales Outstanding 68.96
BIOL's Days Sales Outstanding is ranked higher than
72% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 69.40 vs. BIOL: 68.96 )
BIOL' s 10-Year Days Sales Outstanding Range
Min: 17.25   Max: 223.06
Current: 68.96

17.25
223.06

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 2.20
BIOL's Price/Tangible Book is ranked higher than
87% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.90 vs. BIOL: 2.20 )
BIOL' s 10-Year Price/Tangible Book Range
Min: 3.57   Max: 178.9
Current: 2.2

3.57
178.9
Price/Median PS Value 0.90
BIOL's Price/Median PS Value is ranked lower than
60% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.26 vs. BIOL: 0.90 )
BIOL' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 34.63
Current: 0.9

0.24
34.63
Earnings Yield (Greenblatt) -19.00
BIOL's Earnings Yield (Greenblatt) is ranked higher than
51% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.50 vs. BIOL: -19.00 )
BIOL' s 10-Year Earnings Yield (Greenblatt) Range
Min: -19   Max: 3.7
Current: -19

-19
3.7

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:BTH.Germany,
Biolase Inc was originally formed as Societe Endo Technic, SA ("SET") in 1984 in Marseilles, France. In 1987, SET merged into Pamplona Capital Corp., a public holding company incorporated in Delaware. In 1994, it changed its name to BIOLASE Technology, Inc. and to BIOLASE, Inc. ("BIOLASE") in 2012. The Company is a biomedical company that develops, manufactures, and markets lasers in dentistry and medicine and also markets and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners, and in-office, chair-side milling machines and three-dimensional ("3-D") printers; products that are focused on technologies that advance the practice of dentistry and medicine. Its proprietary dental laser systems allows dentists, periodontists, endodontists, oral surgeons, and other specialists to perform a dental procedures, including cosmetic, restorative, and complex surgical applications. Its systems are designed to provide performance for many types of dental procedures with less pain and faster recovery times than are generally achieved with drills, scalpels, and other conventional instruments. The Company has clearance from the U.S. Food and Drug Administration (the "FDA") to sell its laser systems in the United States and also have the necessary registration to sell its laser systems in Canada, the European Union, and various other international markets. Its licensed dental imaging equipment and other related products are designed to improve diagnoses, applications, and procedures in dentistry and medicine. It offers two categories of laser system products: WaterLase systems and Diode systems. Its WaterLase system, uses a patented combination of water and laser energy to perform most procedures currently performed using dental drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. It currently has approximately 180 issued and 120 pending U.S. and international patents, the majority of which are related to WaterLase technology and dental and medical lasers.
» More Articles for BIOL

Headlines

Articles On GuruFocus.com
Viral Cross-Contamination Risks at the Dentist Office Jan 14 2015 
UPDATE - Ebola and Other Viral Cross-Contamination Risks at the Dentist Office Jan 14 2015 

More From Other Websites
BIOLASE, INC Financials Mar 13 2015
BIOLASE Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) Mar 12 2015
BIOLASE Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) Mar 12 2015
10-K for BIOLASE, Inc. Mar 08 2015
BIOLASE Announces Annual Meeting Date and Record Date Mar 06 2015
BIOLASE Announces Annual Meeting Date and Record Date Mar 06 2015
BIOLASE, INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 06 2015
BIOLASE, INC Files SEC form 10-K, Annual Report Mar 06 2015
Biolase reports 4Q loss Mar 04 2015
Biolase reports 4Q loss Mar 04 2015
BIOLASE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 04 2015
BIOLASE® to Host Fourth Quarter Financial Results Conference Call on March 4, 2015 Mar 04 2015
BIOLASE Reports 2014 Fourth Quarter and Year-End Results Mar 04 2015
BIOLASE Reports 2014 Fourth Quarter and Year-End Results Mar 04 2015
Q3 2014 BIOLASE Inc Earnings Release - Time Not Supplied Mar 04 2015
BIOLASE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or... Mar 02 2015
BIOLASE Names David C. Dreyer Chief Financial Officer Mar 02 2015
BIOLASE Introduces Dentistry’s First-Ever Practice Growth Guarantee™ with the Launch of the New... Mar 02 2015
BIOLASE Names David C. Dreyer Chief Financial Officer Mar 02 2015
BIOLASE Introduces Dentistry’s First-Ever Practice Growth Guarantee™ with the Launch of the New... Feb 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK